ARNI in cardiovascular disease: current evidence and future perspectives.

Published on Apr 22, 2020in Future Cardiology
· DOI :10.2217/FCA-2019-0089
Pramod Kumar Kuchulakanti1
Estimated H-index: 1
(Yashoda Hospitals),
Pramod K. Kuchulakanti17
Estimated H-index: 17
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin receptor II blocker - neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. This trial has provided a strong evidence base for treatment of HFrEF in various subsets of patients. Several studies are done using ARNI in various indications such as HFrEF, HFrEF, patients hospitalized with acute decompensated HF, HF with preserved EF, AMI with LVEF <40%, hypertension, chronic kidney disease, pulmonary hypertension, obstructive sleep apnea, so on and so forth. This review provides an update of current literature and future perspective on ARNI in various cardiovascular disorders.
📖 Papers frequently viewed together
5 Citations
1 Citations
7 Citations
Patients with heart failure and preserved ejection fraction have high morbidity and mortality, as well as reduced quality of life, and there are no approved therapies. The complex pathophysiologica...
7 CitationsSource
#1Hung-Yu Chang (NYMU: National Yang-Ming University)H-Index: 16
#1Hung-Yu Chang (NYMU: National Yang-Ming University)H-Index: 6
Last. Wei-Hsian Yin (NYMU: National Yang-Ming University)H-Index: 19
view all 10 authors...
Abstract Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to reduce cardiovascular mortality by 20% as compared with enalapril in a randomized controlled trial. However, there is a paucity of real-world data on the effects of ARNI in heart failure patients with reduced ejection fraction (HFrEF), especially those with concurrent renal impairment or hypotension. Methods Between 2016 and 2017, we recruited 466 HFrEF patients treated with sacubitril/valsartan (Group A)...
23 CitationsSource
#1James L. Januzzi (Harvard University)H-Index: 110
#2Margaret F. Prescott (Novartis)H-Index: 27
Last. Scott D. Solomon (Brigham and Women's Hospital)H-Index: 149
view all 12 authors...
Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro–b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain. Objective To determine whether NT-proBNP changes in patients with HFrEF treated with sacubitril-valsartan correlate with changes in measures of cardiac volume and function. Design, Setting, and Participants Prospective, 12-month, sing...
148 CitationsSource
#1Scott D. Solomon (Brigham and Women's Hospital)H-Index: 149
#2John J.V. McMurray (Glas.: University of Glasgow)H-Index: 197
Last. Martin LefkowitzH-Index: 56
view all 34 authors...
Abstract Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients ...
498 CitationsSource
#1Vincenzo De SimoneH-Index: 3
#2Paola GuariseH-Index: 3
Last. Giorgio MorandoH-Index: 7
view all 4 authors...
Abstract Pulmonary hypertension due to left heart disease (PH-LHD) frequently complicates heart failure with reduced ejection fraction (HFrEF). Specific therapies for PH have not offered an advantage in patients with PH-LHD. The combined angiotensin receptor blocker–neprilysin inhibitor (ARNI), sacubitril/valsartan, is a novel therapy that can increase levels of natriuretic peptides (NPs). The resulting action on natriuresis and vasodilation may play an important role in the reduction of pulmona...
6 CitationsSource
Aims: To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF). Methods and results: TRANSITION was a randomised, multicentre, open-label study comparing two treatment initiation modalities of sacubitril/valsartan. Patients aged ≥ 18 years, hospitalised for AHF were stratified according to pre-admission use of renin–angiotensin–aldosterone system inhibitors and randomised (n = 1002) after stabilisation to initiate...
85 CitationsSource
#1Duk-Hyun Kang (Asan Medical Center)H-Index: 34
#2Sung-Ji Park (SMC: Samsung Medical Center)H-Index: 16
Last. Jae-Joong Kim (Asan Medical Center)H-Index: 25
view all 10 authors...
Background: The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was...
105 CitationsSource
#1Eric J. Velazquez (Yale University)H-Index: 79
#1Eric J. Velazquez (Yale University)H-Index: 13
Last. Pioneer-Hf InvestigatorsH-Index: 3
view all 9 authors...
Abstract Background Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril–valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. Methods We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilizat...
344 CitationsSource
#1Juan Tamargo (Complutense University of Madrid)H-Index: 78
#2Ricardo Caballero (Complutense University of Madrid)H-Index: 33
Last. Eva Delpón (Complutense University of Madrid)H-Index: 38
view all 3 authors...
ABSTRACTIntroduction: Heart failure (HF) represents a major health problem because of its high prevalence, high rates of hospitalizations, and mortality and significant healthcare costs. HF compris...
8 CitationsSource
#1Richard Haynes (Medical Research Council)H-Index: 30
#2Parminder K. Judge (Medical Research Council)H-Index: 12
Last. Colin Baigent (Medical Research Council)H-Index: 81
view all 16 authors...
Background: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomar...
67 CitationsSource
Cited By2
#1Annayya R. Aroor (MU: University of Missouri)H-Index: 36
#2Srinivas Mummidi (University of Texas at Austin)H-Index: 32
Last. Vincent G. DeMarco (MU: University of Missouri)H-Index: 51
view all 9 authors...
Objective Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity-associated prediabetes, and both serve as risk factors for the development of heart failure with preserved ejection fraction (HFpEF). Since the incidence of DD and arterial stiffness are increasing worldwide due to exponential growth in obesity, an effective treatment is urgently needed to blunt their development and progression. Here we investigated whether the combination of an inhibitor of ...
1 CitationsSource
#1Sepideh TaghaviH-Index: 7
#2Maryam Chenaghlou (Tabriz University of Medical Sciences)
Last. Nasim NaderiH-Index: 13
view all 5 authors...
Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support for increasing survival. Considering the low availability and serious complications of these strategies,effective medical therapies for this group of patients would be pivotal for decreasing mortality ...